Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
GT Biopharma, Inc. entered into Investigator Initiated Clinical Trial Agreement with the Regents of the University of Minnesota valued at up to approximately $3.8 million (effective 2026-04-03).
- Action
- entry
- Agreement
- license
- Counterparty
- the Regents of the University of Minnesota
- Value
- up to approximately $3.8 million
- Effective
- 2026-04-03
Exact text from the filing
On April 3, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), entered into an Investigator Initiated Clinical Trial Agreement (the “Agreement”) with the Regents of the University of Minnesota (the “University”), pursuant to which, the University shall sponsor an Investigational New Drug (“IND”) application for IND 169118 GTB-5550 (the “Research Program”) and shall serve as a sponsor investigator for a phase 1a/1b clinical trial entitled, “GTB-5550, a Camelid Nanobody B7-H3 Tri-Specific Killer Engager (camB7-H3 TriKE®), in Select Advanced Solid Tumors That Failed Prior Therapy,” designed by University (the “Study”).
View on SEC.gov